drugset / Trial / NCT00405964
Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will investigate the effectiveness of desloratadine in treating subjects with allergic rhinitis who meet the criteria for persistent allergic rhinitis (PER)
Timeline
- Start
- 2006-09
- Primary completion
- 2008-04
- Completion
- 2008-04
Outcome
Met primary endpoint
paper with DL than placebo over days 1-29 (-3.76 vs. -2.87, p < 0.001) PMID 20559006 ↗
paper The mean reduction in AM/PM reflective T5SS was significantly greater PMID 20559006 ↗
registry analysis (unspecified test); 5-mg Desloratadine Tablet vs Placebo Tablet; p <.001; ANOVA; note: Determined for site. P-value of \<.001 for treatment as well. NCT00405964 ↗
Publications
- Results Bousquet J, Bachert C, Canonica GW, Mullol J, Van Cauwenberge P, Jensen CB, Fokkens WJ, Ring J, Keith P, Gopalan G, Lorber R, Zuberbier T; ACCEPT-2 Study Group. Efficacy of desloratadine in persistent allergic rhinitis - a GA(2)LEN study. Int Arch Allergy Immunol. 2010;153(4):395-402. doi: 10.1159/000316351. Epub 2010 Jun 18.
- Bousquet J, Zuberbier T, Canonica GW, Fokkens WJ, Gopalan G, Shekar T. Randomized controlled trial of desloratadine for persistent allergic rhinitis: correlations between symptom improvement and quality of life. Allergy Asthma Proc. 2013 May-Jun;34(3):274-82. doi: 10.2500/aap.2013.34.3668.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Desloratadine | Small molecule | 5 mg | — |